Evidence map›Paper›PMID 35938810›Full record

ArticleMicrobiology spectrum2022

Mixed T Helper1/T Helper2/T Cytotoxic Profile in Subjects with Chronic Chagas Disease with Hypersensitivity Reactions to Benznidazole.

Melisa D Castro Eiro, María A Natale, María G Alvarez, Araceli Castro, Débora Seigelshifer, Rodolfo Viotti, Marisa Fernández, Luis Mazzuoccolo, Bruno Lococo, Graciela L Bertocchi and 8 more

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Melisa D Castro Eiro *Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
María A Natale *Instituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.
María G AlvarezHospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.ORCID 0000-0003-4193-9148
Araceli CastroInstituto de Medicina Traslacional, Trasplante y Bioingeniería (IMeTTyB), Universidad Favaloro-CONICET, Buenos Aires, Argentina.
Débora SeigelshiferHospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Rodolfo ViottiHospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Marisa FernándezInstituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.ORCID 0000-0003-1789-4584
Luis MazzuoccoloHospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Bruno LococoHospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Graciela L BertocchiHospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.
Gonzalo CesarInstituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.
María C AlbaredaInstituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.
María J EliasInstituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.
María B CaputoInstituto Nacional de Parasitología Dr. Mario Fatala Chaben, Buenos Aires, Argentina.
Eduardo GaddiHospital Pedro de Elizalde, Buenos Aires, Argentina.
Jeanette BalbaryskiHospital Pedro de Elizalde, Buenos Aires, Argentina.
Carlos A Vigliano *Instituto de Medicina Traslacional, Trasplante y Bioingeniería (IMeTTyB), Universidad Favaloro-CONICET, Buenos Aires, Argentina.
Susana A Laucella *Hospital Interzonal General de Agudos Eva Perón, Buenos Aires, Argentina.ORCID 0000-0001-5224-5446
Administración Nacional de Laboratorios e Institutos de Salud · ARHospital General de Agudos Dr. TEODORO ALVAREZ · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARHospital Pedro de Elizalde · AR

Funding

Immune competence as a factor of treatment efficacy in human Trypanosoma cruzi inR01AI110346 · NIAID · EVA PERON ACUTE INTERZONAL GEN HOSPITAL · PI LAUCELLA, SUSANA ADRIANA · 2014 to 2018
$662k
NIAID NIH HHS R01 AI110346
6 · The paper itself

Abstract

Dermatitis is the most common adverse event during treatment with benznidazole in chronic Chagas disease and is probably mediated by T cells. A set of molecules representative of the different type IV hypersensitivity reactions was evaluated in the circulation and skin biopsies of Trypanosoma cruzi-infected subjects presenting dermatitis during benznidazole administration. Through cytometric bead assays and enzyme-linked immunosorbent assay capture techniques, the serum levels of cytokines, chemokines, proapoptotic molecules, and mediators of the activation and migration of eosinophils and T cells were measured in subjects infected with Trypanosoma cruzi who exhibited skin adverse events (

Indexed as

Chagas DiseaseDermatitisNitroimidazolesTrypanosoma cruziCD8-Positive T-LymphocytesHumansbenzonidazoleNitroimidazolesadverse drug reactionbenznidazoleTrypanosoma cruzi

Identifiers

PMID35938810
PMCPMC9430713
OpenAlexW4290723724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.